Literature DB >> 6761057

Vasodilators in the treatment of hypertension.

K J Osterziel, S Julius.   

Abstract

Vasodilators lower the blood pressure by decreasing total peripheral resistance. The hemodynamic changes depend on the mix between arteriolar and venous dilatation. Since the compensatory responses are blunted with sympatholytic agents and diuretics, vasodilators can be applied effectively in the treatment of hypertension. Hydralazine and prazosin are used as step III drugs in combination with beta-adrenergic blockers and diuretics. Only hypertensive patients whose blood pressure is not controlled by standard antihypertensive drugs should receive minoxidil or captopril. Hypertensives receiving minoxidil usually require a loop diuretic such as furosemide, in addition to a beta-blocker. Captopril is usually combined with a thiazide diuretic and frequently also with a beta-adrenergic blocker. For hypertensive emergencies diazoxide must be injected intravenously as a bolus. It is contraindicated in patients with dissecting aortic aneurysm or left ventricular failure. Sodium nitroprusside is effective in most cases of hypertensive crisis and must be administered intravenously under continuous observation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6761057

Source DB:  PubMed          Journal:  Compr Ther        ISSN: 0098-8243


  2 in total

1.  Pharmacological evaluation of Euphorbia hirta, Fagonia indica and Capparis decidua in hypertension through in-vivo and in vitro-assays.

Authors:  Muhammad Zeeshan Ali; Malik Hassan Mehmood; Muhammad Saleem; Muhammad Sajid Hamid Akash; Abdul Malik
Journal:  Heliyon       Date:  2021-09-30

2.  Design, synthesis, and antihypertensive activity of curcumin-inspired compounds via ACE inhibition and vasodilation, along with a bioavailability study for possible benefit in cardiovascular diseases.

Authors:  Xiao-Dong Zhuang; Li-Zhen Liao; Xiao-Bian Dong; Xun Hu; Yue Guo; Zhi-Min Du; Xin-Xue Liao; Li-Chun Wang
Journal:  Drug Des Devel Ther       Date:  2016-01-05       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.